Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

Yusof, M. MdCescon, D. W.Rugo, H. S.Im, S-A.Gallardo, C.Lipatov, O.Gokmen, E.2021-05-032021-05-0320200923-75341569-8041https://doi.org/10.1016/j.annonc.2020.10.063https://hdl.handle.net/11454/70273[No Abstract Available]en10.1016/j.annonc.2020.10.063info:eu-repo/semantics/openAccess[No Keyword]Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in AsiaConference Object31S1257S1257WOS:000600988900044Q1